Abstract
The effects of clozapine on the dopamine and serotonin systems may underlie its atypical pharmacologic and clinical profile. To examine this hypothesis, we measured dopamine and serotonin plasma and cerebrospinal (CSF) metabolites and the relationship of these values to treatment response in 19 neuroleptic refractory and intolerant schizophrenic patients. Only a small change in the CSF and plasma homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) levels was found. However, the pretreatment CSF HVA/5HIAA ratio and, to a lesser extent, the CSF HVA level predicted treatment response. These results suggest that the modest relationship between HVA and 5-HIAA and treatment response supports the involvement of both neurotransmitters in the pathophysiology of schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achenheil M, Blatt B, Lampart C (1975) Effect of clozapine on 5HIAA excretion in urine and CSF of psychotic patients and on serotonin metabolism in rat brain. Acta Vitaminol Enzymol 29:79–81
Agren H, Mefford IN, Rudorfen MV, Linnoila M, Potter WZ (1986) Interacting neurotransmitter systems. A non-experimental approach to the 5-HIAA-HVA correlation in human CSF. J Psychiatr Res 20:175–193
Bartholini G, Halfely W, Jalfre M, Keller HH, Pletscher A (1972) Effect of clozapine on cerebral catecholominergic neurone systems. Br J Pharmacol 46:736–740
Deutsch AG, Moghaddam B, Innis R, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121–156
Fri CG, Wiesel FA, Sedvall G (1974) Simultaneous quantification of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid by mass fragmentography. Life Sci 14:2469–2480
Friedman RL, Sanders-Bush E, Barett RL (1985) Clozapine blocks disruptive and discriminative stimulus effects of quipazine. Eur J Pharmacol 106:191–193
Gerlach J, Thorsen K, Fog R (1975) Extrapyramidal reactions and amino metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology 40:341–350
Guy W (1976) Clinical Global Impression Scale. In: EDCEU Assessment Manual. US Department of Health Education and Welfare, pp 218–222
Honigfeld G, Paten J, Singer J (1984) Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1:77–97
Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45:789–796
Lieberman JA, Saltz BL, Johns CA, Pollock S, Kane JM (1984) Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 25:57–62
Meltzer HY, Bastoni B, Ramirez L, Matsurbara S (1989a) Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 238:332–339
Meltzer HY (1989b) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:518–527
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 49:345–353
Simpson GM, Cooper TD (1978) Clozapine plasma levels and convulsions. Am J Psychiatry 135:99–100
Simpson GM, Lee JH, Zoubek B (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64:171–179
Woerner MG, Mannuzza S, Kane JM (1988) Anchoring the Brief Psychiatric Rating Scale; an aid to improve reliability. Psychopharmacol Bull 24:112–117
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szymanski, S., Lieberman, J., Pollack, S. et al. The dopamine-serotonin relationship in clozapine response. Psychopharmacology 112 (Suppl 1), S85–S89 (1993). https://doi.org/10.1007/BF02245011
Issue Date:
DOI: https://doi.org/10.1007/BF02245011